Erstellt am 15 Nov 2022 13:57
Zuletzt geändert: 17 Jun 2024 12:15
Therapie-Ansatz HBO
- Hadanny A, Zilberman-Itskovich S, Catalogna M, Elman-Shina K, Lang E, Finci S, Polak N, Shorer R, Parag Y, Efrati S. Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial. Sci Rep. 2024 Feb 15;14(1):3604. doi: 10.1038/s41598-024-53091-3. PMID: 38360929; PMCID: PMC10869702.
- Authors; Basharat S, Spry C. Hyperbaric Oxygen Therapy: An Emerging Therapy for Post–COVID-19 Condition: CADTH Horizon Scan [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Aug. Report No.: EN0050. PMID: 37934848.
- Kjellberg A, Hassler A, Boström E, El Gharbi S, Al-Ezerjawi S, Kowalski J, Rodriguez-Wallberg KA, Bruchfeld J, Ståhlberg M, Nygren-Bonnier M, Runold M, Lindholm P. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis. 2023 Jan 20;23(1):33. doi: 10.1186/s12879-023-08002-8. PMID: 36670365; PMCID: PMC9854077.
- Siewiera J, Brodaczewska K, Jermakow N, Lubas A, Kłos K, Majewska A, Kot J. Effectiveness of Hyperbaric Oxygen Therapy in SARS-CoV-2 Pneumonia: The Primary Results of a Randomised Clinical Trial. J Clin Med. 2022 Dec 20;12(1):8. doi: 10.3390/jcm12010008. PMID: 36614808; PMCID: PMC9820955.
Abstract
Mortality in COVID-19 is mainly associated with respiratory failure, cytokine storm, and macrophage activation. Oxygenation and anti-inflammatory effects of Hyperbaric Oxygen Therapy (HBOT) suggest that it is a promising adjunct treatment for COVID-19. Repeated sessions of HBO with standard COVID-19 therapy were used to reduce the inflammation and increase oxygenation. We evaluated the safety and efficacy of HBOT in avoiding the replacement ventilation and/or ECMO and its effect on the inflammatory process. Twenty-eight moderate-to-severe COVID-19 patients were randomized into control or HBOT group. HBOT patients participated in 5 hyperbaric sessions (60 min). Before and after each session blood gas levels and vital parameters were monitored. Blood samples were collected for extended biochemical tests, blood morphology and immunological assays. There were 3 deaths in the control, no deaths in the HBOT group. No adverse events leading to discontinuation of HBOT were observed and patients receiving HBOT required lower oxygen delivery. We observed decrease in CRP, ferritin and LDH and increase in CD3 in HBOT group compared to control. This study confirmed the feasibility and safety of HBOT in patients with COVID-19 and indicated HBOT can lead to alleviation of inflammation and partial restoration of T cell responses.
- Kjellberg A, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Boström E, Sundberg CJ, Pernow J, Medson K, Kowalski JH, Rodriguez-Wallberg KA, Zheng X, Catrina S, Runold M, Ståhlberg M, Bruchfeld J, Nygren-Bonnier M, Lindholm P. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open. 2022 Nov 2;12(11):e061870. doi: 10.1136/bmjopen-2022-061870. PMID: 36323462; PMCID: PMC9638753. Clinicaltrials: https://clinicaltrials.gov/study/NCT04842448. Study Completion (Estimated): 2024-07-30.
- Robbins T, Gonevski M, Clark C, Baitule S, Sharma K, Magar A, Patel K, Sankar S, Kyrou I, Ali A, Randeva HS. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond). 2021 Nov;21(6):e629-e632. doi: 10.7861/clinmed.2021-0462. PMID: [https://pubmed.ncbi.nlm.nih.gov/34862223/34862223]; PMCID: PMC8806311.
Methods: A total of 10 consecutive patients received 10 sessions of HBOT to 2.4 atmospheres over 12 days. Each treatment session lasted 105 minutes, consisting of three 30-minute exposures to 100% oxygen, interspersed with 5-minute air breaks. Validated fatigue and cognitive scoring assessments were performed at day 1 and 10. Statistical analysis was with Wilcoxon signed-rank testing reported alongside effect sizes.
Results: HBOT yielded a statistically significant improvement in the Chalder fatigue scale (p=0.0059; d=1.75 (very large)), global cognition (p=0.0137; d=-1.07 (large)), executive function (p=0.0039; d=-1.06 (large)), attention (p=0.0020; d=-1.2 (very large)), information processing (p=0.0059; d=-1.25 (very large)) and verbal function (p=0.0098; d=-0.92 (large)).
Wilmshurst P, Bewley S, Murray P. Hyperbaric oxygen therapy for the treatment of long COVID. Clin Med (Lond). 2023 Jan;23(1):99-100. doi: 10.7861/clinmed.Let.23.1.2. PMID: 36697009; PMCID: PMC11046540. Kritischer Kommentar zu Robbins.
- Oliaei S, SeyedAlinaghi S, Mehrtak M, Karimi A, Noori T, Mirzapour P, Shojaei A, MohsseniPour M, Mirghaderi SP, Alilou S, Shobeiri P, Azadi Cheshmekabodi H, Mehraeen E, Dadras O. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review. Eur J Med Res. 2021 Aug 19;26(1):96. doi: 10.1186/s40001-021-00570-2. PMID: 34412709; PMCID: PMC8374420.
Systematic review:
Results: Eight articles from three countries were included. All the included studies had good and fair quality scores, with no poor studies included in this systematic review (Good: n = 5, Fair: n = 3). Studies were divided into clinical trials and case reports/series. Most of the studies used HBOT less than 1.5-2 absolute atmospheres (ATA) for 90 min sessions and thereafter sessions were decreased to 60 min. Trials demonstrated most of the patients recovered after receiving HBOT, and blood oxygen saturation increased after several sessions of HBOT.
Grundsätzliches zu HBO-Studien
- Lansdorp CA, van Hulst RA. Double-blind trials in hyperbaric medicine: A narrative review on past experiences and considerations in designing sham hyperbaric treatment. Clin Trials. 2018 Oct;15(5):462-476. doi: 10.1177/1740774518776952. Epub 2018 Jun 4. PMID: 29865904; PMCID: PMC6136075.
Artikel zum Thema Covid-19 auf Wikidot
- Covid 19: Ländervergleiche
- COVID-19 - data & numbers
- Infektionsgeschehen und Infektionsbekämpfung
- Covid 19: Public-Health-Maßnahmen
- Covid 19: Transmission
- Covid 19: Ventilation
- Covid 19: Therapie
- Rekonvaleszenten-Plasma
- Covid 19: Immunantworten
- Covid 19: Impfstoffe
- Covid 19: Post-Infektions oder Impfdurchbrüche
- Covid 19: Impfungen, Nebenwirkungen, Schäden
- Covid 19: Impfschäden, Post-Covid-Vakzine-Syndrom
- Covid-19: Spätschäden, Long-Covid & Post-Covid
- Post-COVID Epidemiologie
- Post-Covid: Symptome & Störungsbilder
- Post Covid: Schadensbilder
- Post-Covid-ME/CFS: Sozialrecht
- Post-Covid: Sozialrecht
- Post-Covid: Therapie-Ansatz Apherese
- Post-Covid: Therapie-Ansatz BC007
- Post-Covid: Therapie-Ansatz HBO
Die Beiträge in diesem Wiki zu "Erkrankungen und Behinderungen", gesundheitlichen Problemlagen und Indikationen erheben weder den Anspruch, umfassend noch hinsichtlich der Einsortierung in einer Rubrik immer unstrittig zu sein.
Die Beiträge sind aus sozialmedizinischem Blickwinkel und mit dem Schwerpunkt der sozialmedizinischen Begutachtung einsortiert. Aus der Einordnung in einer Rubrik resultiert weder eine Wertung noch eine objektive Feststellung hinsichtlich der Bedeutung einer gesundheitlichen Problemlage/Erkrankung.
Alle Darstellungen medizinischer Sachverhalte, Erkrankungen und Behinderungen und deren sozialmedizinische Einordnung und Kommentierungen hier im Wiki dienen nicht einer "letzt begründenden theoretisch-wissenschaftlichen Aufklärung", sondern sind frei nach Karl Popper "Interpretationen im Licht der Theorien."*
* Zitat nach: Bach, Otto: ''Über die Subjektabhängigkeit des Bildes von der Wirklichkeit im psychiatrischen Diagnostizieren und Therapieren''. In: Psychiatrie heute, Aspekte und Perspektiven, Festschrift für Rainer Tölle, Urban & Schwarzenberg, München 1994, ISBN 3-541-17181-2, (Zitat: Seite 1)
Alle medizinischen Aussagen und Informationen in diesem Wiki dienen nicht der medizinischen Beratung und können und sollen eine persönliche fachliche ärztliche Beratung nicht ersetzen!
Neue Seite anlegen